NanoMed Pty Ltd is a nanobiotech company based in Sydney, Australia. Our mission is to design, develop and commercialise colloidal nanomedicines for use as cancer therapeutics and diagnostic imaging agents.
NCI is the leading national institution for high performance computing, and provides world-class high-end services to more than 4,000 Australian researchers from 31 universities, five science agencies and several medical research institutes.
The National Health and Medical Research Council (NHMRC) is Australia’s leading expert body promoting the development and maintenance of public and individual health standards.
NextMed Capital's mission is to nurture the seeds of the next generation of medical innovation. The company was founded in 2016 with the goal of becoming Australia's leading very early stage innovation and medical technology investor. NextMed Capital can invest in projects as early as the pre-clinical phase and adds significant value to its investments through leveraging the combined commercial, entrepreneurial, project management, financing, business planning and academic skills of its experienced management team.
Formed in October 2013, NIESM is a Melbourne-based Australian company that delivers clinician support tools focused around wearable technologies and an enterprise software platform to provide optimal health outcomes for patients with epilepsy. NIESM has put together a global team with world leaders in technology, clinical and business capabilities and they are committed to helping patients become seizure free.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies.
Novita Healthcare is an emerging health sector technology company encompassing the current businesses of TALI Health and Newly. The TALI system uses proprietary software algorithms to monitor and assist in the treatment of cognitive problems such as attention difficulties in early childhood.
Nucleus Network is a leading early phase clinical research organisation in Australia, providing an expedited regulatory pathway, the CTN scheme, for the initiation of first-in-human clinical trials without the need for filing an IND.